Cantabio Pharmaceuticals (CTBO) 10-K 16 Jul 18 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2018	Jul. 09, 2018	Sep. 30, 2017
Document and Entity Information
Entity Registrant Name	Cantabio Pharmaceuticals Inc.
Document Type	10-K
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Entity Central Index Key	1,550,518
Current Fiscal Year End Date	--03-31
Entity Common Stock, Shares Outstanding		53,863,584
Entity Public Float			$ 0
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Trading Symbol	ctbo

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Current Assets
Cash	$ 109,426	$ 32,275
Prepaid expenses		1,248
Total Current Assets	109,426	33,523
TOTAL ASSETS	109,426	33,523
Current Liabilities
Accounts payable and accrued expenses	606,751	377,893
Accrued technology access fee	171,105	140,142
Convertible debentures	947,160	322,256
Convertible debentures related party	257,614
Notes payable related party		47,154
Total Current Liabilities	1,982,630	887,445
TOTAL LIABILITIES	1,982,630	887,445
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock value	51,857	26,805
Stock subscriptions	1,060,000	1,060,000
Additional paid-in capital	1,134,763	167,324
Accumulated deficit	(4,119,824)	(2,108,051)
Total Stockholders' Equity (Deficit)	(1,873,204)	(853,922)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 109,426	$ 33,523

Balance Sheets (parenthetical)

Balance Sheets (parenthetical) - $ / shares	Mar. 31, 2018	Mar. 31, 2017
Balance Sheet
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	51,857,201	26,805,270
Common stock, shares outstanding	51,857,201	26,805,270

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement
Revenues
Operating Costs and Expenses
Research and development expense	371,041	350,310
General and administrative expenses	977,747	718,959
Total operating costs and expenses	1,348,788	1,069,269
Income (loss) from operations	(1,348,788)	(1,069,269)
Other Income and Expenses
Interest expense	619,960	39,869
Change in fair value of embedded derivative	198,000	(3,000)
Gain (loss) on extinguishment of debt	(241,025)
Total other income and (expenses)	(662,985)	(42,869)
Net income (loss)	$ (2,011,773)	$ (1,112,138)
Basic and diluted earnings (loss) per share	$ (0.07)	$ (0.04)
Weighted average common shares outstanding - basic and diluted	30,943,829	26,805,270

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Common Shares	Common Stock Subscriptions	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance, shares at Mar. 31, 2016	26,805,270
Beginning Balance, amount at Mar. 31, 2016	$ 26,805	$ 500,000	$ 99,324	$ (995,913)	$ (369,784)
Stock subscriptions		560,000			560,000
Beneficial conversion feature - convertible debentures			68,000		68,000
Net income (loss) for the period				(1,112,138)	(1,112,138)
Ending Balance, shares at Mar. 31, 2017	26,805,270
Ending Balance, amount at Mar. 31, 2017	$ 26,805	1,060,000	167,324	(2,108,051)	(853,922)
Beneficial conversion feature - convertible debentures			35,000		35,000
Stock-based compensation, shares	7,520,498
Stock-based compensation, value	$ 7,520		352,924		360,444
Stock issued to satisfy accrued expenses, shares	7,400,000
Stock issued to satisfy accrued expenses, value	$ 7,400		343,160		350,560
Stock issued upon conversion of debt, shares	10,131,433
Stock issued upon conversion of debt, value	$ 10,132		236,355		246,487
Net income (loss) for the period				(2,011,773)	(2,011,773)
Ending Balance, shares at Mar. 31, 2018	51,857,201
Ending Balance, amount at Mar. 31, 2018	$ 51,857	$ 1,060,000	$ 1,134,763	$ (4,119,824)	$ (1,873,204)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$ (2,011,773)	$ (1,112,138)
Adjustments to reconcile net loss to net cash used by operating activities:
Gain (loss) on extinguishment of debt	(241,025)
Accretion to notes payable to related party		1,807
Amortization of debt discount	533,651	22,756
Change in fair value of embedded derivative	198,000	(3,000)
Stock issued in lieu of services	360,444
Changes in operating assets and liabilities:
(Increase) decrease in accounts payable and accrued expenses	378,372	152,395
(Increase) decrease in accrued technology fee	30,963	(33,272)
(Increase) decrease in accrued debenture interest	40,721
Increase (decrease) in prepaid expenses	1,248	(1,248)
(Increase) decrease in due to officers		(6,420)
Net cash provided by (used in) operating activities	(623,349)	(973,120)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party notes payable		59,368
Repayments of related party notes payable		30,583
Proceeds from issuance of convertible debentures	405,500	364,500
Proceeds from issuance of convertible debentures related party	295,000
Proceeds from stock subscriptions		560,000
Net cash provided by financing activities	700,500	953,285
Net increase (decrease) in cash	77,151	(19,835)
Cash, beginning of period	32,275	52,110
Cash, end of period	109,426	32,275
Schedule of non-cash financing activities
Beneficial conversion feature - convertible debentures	35,000	$ 68,000
Conversion of secured convertible debentures into common shares	$ 307,000

Organization and Description of

Organization and Description of The Business	12 Months Ended
	Mar. 31, 2018
Notes
Organization and Description of The Business	NOTE 1 - ORGANIZATION AND DESCRIPTION OF THE BUSINESS Cantabio Pharmaceuticals Inc. (the “Company” or “Cantabio”) is a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from research and development activities for Parkinson’s disease (PD) and Alzheimer’s disease (AD). The Company’s strategy involves integration of therapeutic focus, the targeting of family biophysics, drug discovery technology and expertise into an innovative drug discovery approach, which synergizes to identify and develop small molecule pharmacological chaperones for clinical trials. In addition, the Company’s research efforts concentrate on the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins with display loss of function during disease conditions.

Going Concern Disclosure

Going Concern Disclosure	12 Months Ended
	Mar. 31, 2018
Notes
Going Concern Disclosure	NOTE 2 - GOING CONCERN As of March 31, 2018 the Company had a working capital deficit of $1,873,204 and losses from operations. The Company typically raises capital which it spends on maintaining its research and corporate operations. At this early stage in the life of the company funding is often short term in nature. While the Company has been proficient in raising funds in the past, the short-term nature of these funding cycles raises substantial doubt about the Company's ability to continue as a going concern within one year from the date of this filing. Management is addressing going concern risk by seeking new sources of capital and is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet future working capital requirements. Furthermore, strategic partnerships, most likely with larger pharmaceutical industry companies, will be needed to continue to fund research and development costs as our projects expand. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company beyond the next twelve months. The ability of the Company to continue as a going concern is dependent upon its ability to raise additional capital and achieve profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2018
Notes
Summary of Significant Accounting Policies	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Principles of Consolidation These financial statements include the accounts of the Company and its wholly-owned subsidiary. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates. Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company's statements of operations. The fair value of the warrants issued by the Company has been estimated using a valuation pricing model, at each measurement date that incorporates various inputs including remaining contractual term, stock volatility, risk free rate and dividend yield. Equity-linked Financial Instruments Certain of the Company’s debt instruments include embedded derivatives that require bifurcation from the host contract under the provisions of ASC 815, Derivatives and Hedging. Under this guidance, the Company recognizes the embedded derivatives at fair value and records a gain or loss resulting from the change in fair values at the end of each reporting period. In connection with issuance of the Company’s Zhu convertible notes, beginning on July 3, 2017, the Company became contingently obligated to issue shares in excess of the 250 million authorized by shareholders. Consequently, the ability to settle these obligations with shares would be unavailable causing these and other share-settled obligations to potentially be settled in cash. The Company applies a sequencing policy regarding share settlement wherein equity-linked financial instruments with the earliest issuance date would be settled first. Thus, all equity-linked financial instruments, which are convertible or exercisable into common stock, issued concurrent or subsequent to the Zhu Notes are classified as derivative liabilities, with the exception of instruments related to employee share-based compensation. Sequencing As of July 3, 2017, the Company adopted a sequencing policy whereby all future equity-linked instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors. Income Taxes The Company recognizes income taxes on an accrual basis based on tax positions taken or expected to be taken in its tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. Fair Value of Financial Instruments The Company's financial instruments consist of cash, accounts payable, convertible debentures and a loan payable to a related party. The carrying amounts of these financial instruments approximate fair value due either to length of maturity or interest rates that approximate prevailing rates unless otherwise disclosed in these financial statements. Share Subscriptions Under the terms of a subscription agreement, the Company has received funds in advance of the issuance of stock. The stock is issuable to the investors once the full subscription proceeds are received, which, as of the date of this filing, has not yet occurred. The Company recorded the advance in equity. Earnings (Loss) per Share The Company calculates earnings per share using basic net income (loss) per common share be computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. The Company does not compute diluted earnings per share because to do so would be anti-dilutive. March 31, March 31, 2018 2017 Potentially dilutive securities Secured convertible debentures (Note 6) 12,406,000 3,420,000 Convertible debt related party (Note 7) 3,914,000 -- Stock subscription 530,000 530,000 Recently Issued Accounting Standards Fiscal 2018 Accounting Pronouncement Adoptions In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Certain qualitative and quantitative disclosures are required, as well as a retrospective recognition and measurement of impacted leases. The new ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements. In June 2018, the FASB issued Accounting Standards Update (ASU) 2018-07 intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. This ASU expands the scope of Topic 718, Compensation-Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity-Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other companies, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company's adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements.

Material Agreements Disclosure

Material Agreements Disclosure	12 Months Ended
	Mar. 31, 2018
Notes
Material Agreements Disclosure	NOTE 4 - MATERIAL AGREEMENTS The following material agreements are important to our research and development activities: Agreement with NovAliX Deutschland GmbH On March 23, 2016, we entered into a collaboration agreement with NovAliX Deutschland GmbH, in which NovAliX granted us a worldwide, perpetual, non-exclusive license, including the right to sublicense, under (i) any and all patent rights owned or controlled by NovAliX that claim or cover any chemical compound and (ii) any and all technology generated by NovAliX in the performance of the Agreement and related to selected series of compounds (the “Hit Series Compounds”) from the NovAliX chemical microarrays showing binding and Structure Activity Relation trends to the A peptide. The terms of the agreement required an initial payment of approximately $80,000, payable at some point within four years, which would accrue interest at 20% per annum from the date of signing until the balance is paid. A further payment of approximately $80,000 is payable upon commercialization of the technology. As at March 31, 2018 the total of accrued interest was approximately $35,000. Purdue Research Foundation Licensing Agreement - DJ-1 Small Molecule On April 1, 2016, we entered into a trade secret license agreement with Purdue Research Foundation (“PRF”). Pursuant to this agreement, we received licenses to use certain information generated at Purdue University related to the DJ-1 compounds. These licenses include a worldwide, exclusive license to use that information to manufacture, use and sell products to diagnose, prevent and treat diseases and a worldwide, non-exclusive license under PRF’s rights in any invention for research and development of DJ-1 compounds. The license fee is $50,000, payable in five equal annual installments. The first two installments came due in July 2016 and July 2017 and both have been paid. Three installments remain ($150,000). Cambridge Enterprise Licensing Agreement - Tau On September 7, 2016, we entered into a global licensing agreement with Cambridge Enterprise to use technology generated in the Tau small molecule project conducted at Cambridge University in conjunction with the Max Planck Institute run by Dr. Gergely Tóth at the University of Cambridge. The agreement defined an initial payment of approximately $13,000 which has been paid by the Company, followed by further payments upon reaching the following milestones: i) Internal Declaration of Candidate - approximately $13,000 for technology based patents or approximately $25,000 for data based patents; ii) First dose in man or initiation of any Phase I Trial of each Licensed Product - approximately $100,000 for technology based patents or approximately $200,000 for data based patents; iii) Initiation of any phase II trial of each Licensed Product - approximately $140,000 for technology based patents or approximately $280,000 for data based patents; iv) Initiation of any phase III trial of any Licensed Product - approximately $140,000 for technology based patents or approximately $700,000 for data based patents; v) First approval or marketing authorisation of each Licensed Product in the United States or European Union - approximately $140,000 for technology based patents or approximately $700,000 for data based patents; and vi) Reimbursement approval in the U.S. - approximately $140,000 for technology based patents or approximately $700,000 for data based patents. Work continues on projects under this agreement, although to date none of these milestones have been reached.

Related Party Transactions Disc

Related Party Transactions Disclosure	12 Months Ended
	Mar. 31, 2018
Notes
Related Party Transactions Disclosure	NOTE 5 - RELATED PARTY TRANSACTIONS Approximate costs incurred associated with related party transactions included in general and administrative in the statement of operations, including stock based compensation, are as follows: Years to March 31 2018 2017 Operating expenses: Toth and Associates LTD $ 320,000 $ 144,000 Capro LTD 207,000 120,000 Eden Professional LTD 147,000 75,000 Max Zhu Consulting 18,000 24,000 Total related party transactions $ 692,000 $ 363,000 Accounts payable and accrued expenses includes amounts payable to related parties of $0.2 and $0.3 million for the fiscal years ended March 31, 2018 and March 31, 2017, respectively. Toth and Associates LTD On July 1, 2016, the Company entered into a consulting agreement with Toth and Associates, LTD for Dr. Toth to act as the Company’s CEO. The agreement calls for a standard monthly fee of approximately $12,000 plus any additional uncontracted hours at the same rate, and bonuses as follows (A) upon raising of capital on behalf of, or as part of the Company, an amount equal to 1.5% of the capital raised, (B) increasing the performance of the Company as measured by valuation in either an agreed valuation in the context of an investment or, in the case of a public company, market capitalization reaching $30.0 million, a fixed bonus of $50,000, payable wholly or in mutually agreed tranches over a 6 month period subsequent to the valuation event, (C) on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital and (D) in the event of the Company, including any affiliated entities, securing a licensing agreement with any 3rd party, an amount equivalent to 1.5% of any payments to the Company under such licensing agreement. Capro LTD On July 1, 2016, the Company entered a consulting agreement with Capro, LTD for Dr. Thomas Sawyer to act as the Company’s COO. The agreement calls for a standard monthly fee of approximately $10,000 plus any additional uncontracted hours at the same rate, and bonuses as follows (A) upon raising of capital on behalf of, or as part of the Company, an amount equal to 1.5% of the capital raised, (B) increasing the performance of the Company as measured by valuation in either an agreed valuation in the context of an investment or, in the case of a public company, market capitalization reaching $30.0 million, a fixed bonus of $50,000, payable wholly or in mutually agreed tranches over a 6 month period subsequent to the valuation event and (C) on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital and (D) in the event of the Company, including any affiliated entities, securing a licensing agreement with any 3rd party, an amount equivalent to 1.5% of any payments to the Company under such licensing agreement. Eden Professional LTD On July 1, 2016, the Company entered a consulting agreement with Eden Professional LTD for Mr. Simon Peace to act as the Company’s CFO. The agreement calls for a standard monthly fee of approximately $6,000 plus any additional uncontracted hours at the same rate, and bonuses as follows (A) upon raising of capital on behalf of, or as part of the Company, an amount equal to 1.5% of the capital raised, (B) increasing the performance of the Company as measured by valuation in either an agreed valuation in the context of an investment or, in the case of a public company, market capitalization reaching $30.0 million, a fixed bonus of $50,000, payable wholly or in mutually agreed tranches over a 6 month period subsequent to the valuation event and (C) on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital and (D) in the event of the Company, including any affiliated entities, securing a licensing agreement with any 3rd party, an amount equivalent to 1.5% of any payments to the Company under such licensing agreement. Max Zhu Max Zhu, an investor and lender to the Company, also works as Head of Computer Aided Drug Design for the Company under a consultancy contract.

Secured Convertible Debentures

Secured Convertible Debentures Disclosure	12 Months Ended
	Mar. 31, 2018
Notes
Secured Convertible Debentures Disclosure	NOTE 6 - SECURED CONVERTIBLE DEBENTURES Original issuances The Company has entered into several securities purchase agreements during 2017 and 2018 with an accredited investor to place Convertible Debentures (as amended the “Debentures”) in the aggregate principal amount of up to $900,000 (the “Transaction”), provided that in case of an event of default, the Debentures may become at the holder’s election immediately due and payable. The Debentures bear interest at the rate of 5% per annum. In addition, the Company must pay to the holder an annual fee equal to 7% of the amount of the Debentures to assist in their monitoring costs for the Debentures. The net proceeds of the financing were used for general corporate matters and for other expenses. Conversion Feature The Debentures may be converted at any time on or prior to maturity at the lower of $0.10 or 93% of the average of the three lowest daily volume weighted average price (“VWAP”) during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the Debenture and the conversion price is never lower than a stated floor price. The Debentures have been amended several times, including most recently in the third quarter with the addition that the floor price being $0.01 and the due date November 2018. Monthly Redemption Feature Any time after the six-month anniversary of the issuance of a Debenture that the daily VWAP is less than $0.01 for a period of twenty consecutive trading days (the “Triggering Date”) and only for so long as such conditions exist after a Triggering Date, the Company shall make monthly payments beginning on the last calendar day of the month when the Triggering Date occurred. Each monthly payment shall be in an amount equal to the sum of (i) the principal amount outstanding as of the Triggering Date divided by the number of such monthly payments until maturity, (ii) a redemption premium of 20% in respect of such principal amount and (iii) accrued and unpaid interest hereunder as of each payment date. The Company may, no more than twice, obtain a thirty-day deferral of a monthly payment due as a result of a Triggering Date through the payment of a deferral fee in the amount equal to 10% of the total amount of such monthly payment. Each deferral payment may be paid by the issuance of such number of shares as is equal to the applicable deferral payment divided by a price per share equal to 93% of the average of the four lowest daily VWAPs during the 10 consecutive Trading Days immediately preceding the due date in respect of such monthly payment begin deferred, provided that such shares issued will be immediately freely tradable shares in the hands of the holder. In the third quarter a Triggering Date occurred and the Company recorded a premium of $50,000 included in accounts payable and accrued expense. Extinguishment of Notes In the third quarter the Company, entered into an amended agreement with the investor which included a change to the due date and an adjustment to the floor price. The terms of the new debt instrument was considered to be substantially different such that the changes were sufficient to recognize the amendment as an extinguishment of the debt. A loss on extinguishment of $241,025 was recorded in other income (expense). Debt discount of approximately $0.6 million was recorded as a result of the new issuance due to the conversion features. Beneficial Conversion Feature At the time of each closing, the Debenture’s effective conversion price was below the quoted market price of the Company’s common stock. As such, the Company recognized a beneficial conversion feature equal to the intrinsic value of the conversion feature on each issuance date, resulting in a discount to the Debenture with a corresponding credit to additional paid-in capital. Embedded Derivatives The monthly payment provision within the Debentures is a contingent put option that is required to be separately measured at fair value, with subsequent changes in fair value recognized in the Consolidated Statements of Operations. The Company estimated the fair value of the monthly payment provision using probability analysis of the occurrence of a Triggering Date applied to the discounted maximum redemption premium for any given payment. The probability analysis utilized in calculating the embedded derivative was calculated using the following key inputs: March 31, 2018 March 31, 2017 Stock price $0.06 $0.16-$0.23 Probability of Triggering Date 100% 23%-35% Volatility 300% 207% Risk-free rate 1% 1% Discount rate 0% 40% Due to the Company’s sequencing policy the Company recorded an embedded derivative associated with the debentures conversion feature. The following are the inputs associated with the embedded conversion feature. March 31, 2018 March 31, 2017 Stock price $0.06 $0.16-$0.23 Exercise price $0.06 $0.15-$0.21 Volatility 300% 207% Contractual term 1 year 1 year Risk-free rate 1% 1% Discount rate 0% 40% The fair value estimate of the embedded derivatives is a Level 3 measurement. The roll-forward of the Level 3 fair value measurement is as follows: Balance at March 31, 2017 Issuance Net unrealized (gain)/loss Balance at March 31, 2018 24,000 $ 685,000 $ 27,000 $ 736,000 The carrying value of the Debentures is comprised of the following: March 31, 2018 March 31, 2017 Secured Convertible Debentures Principal $ 750,000 $ 450,000 Fair value of embedded derivative 736,000 24,000 Accrued interest 22,264 -- Debt discount (561,104) (151,744) Carrying value of Secured Convertible Debentures $ 947,160 $ 322,256 As of March 31, 2018, the estimated aggregate fair value of outstanding convertible notes payable is approximately $0.9 million. The fair value estimate is based on the estimated option value of the conversion terms. The estimated fair value represents a Level 3 measurement. Converted Debentures During the year ended March 31, 2018, holders of approximately $0.2 million in principal amount and accrued interest with respect to Secured Convertible Debentures exercised the conversion option and converted into 4.2 million shares of common stock. Events of Default or Financial covenants The Company is in compliance with all terms associated with the convertible note.

Convertible Debt Related Partie

Convertible Debt Related Parties Disclosure	12 Months Ended
	Mar. 31, 2018
Notes
Convertible Debt Related Parties Disclosure	NOTE 7 - CONVERTIBLE DEBT RELATED PARTIES Convertible notes, 18%-28% During the year ended March 31, 2018 the Company issued convertible notes payable to Max Zhu for an aggregate principal balance of $220,000, in exchange for cash of $175,000 and the exchange of a note payable to Mr. Zhu with a principal balance of $45,000. The extinguished note payable was fully matured. The convertible notes had interest rates ranging from 18% to 28%. In January 2018 the holder converted $120,000 of principal and $14,994 of interest into approximately 6.0 million shares of common stock. The remaining $100,000 convertible note payable from this tranche had a six-month term, maturing in February 2018, incurring interest at 23% through maturity and 28% thereafter. The Company has the option to settle the principal and all accrued interest of each note in cash or shares. The note holder has the right to convert all or any portion of the outstanding principal and accrued interest of the 28% note into common shares of the Company at a conversion price of the lesser of: (i) $0.08 per share, or (ii) a price equal to 80% of the lowest VWAP during the five consecutive days before the notice of conversion. Convertible note, 5% In January 2018 the Company issued a further convertible note to Mr. Zhu in exchange for $120,000. The note has a twelve month term and bears interest at the rate of 5% per annum. In addition, the Company must pay to the holder an annual fee equal to 7% of the amount of the note to assist in his monitoring costs. The 5% note may be converted at any time at the lower of $0.10 or 93% of the average of the three lowest daily volume weighted average price (“VWAP”) during the 10 consecutive trading days immediately preceding the conversion date, provided that we are not in default under the Debenture and the conversion price is never lower than a stated floor price. The analysis utilized in calculating the embedded derivative upon issuance and at March 31, 2018 was calculated using the following key inputs: Key Inputs Stock price $0.02- $0.07 Contractual term 0.1 - 1.0 years Volatility 275%-300% Risk-free rate 1% The fair value estimate of the embedded derivative is a Level 3 measurement. The roll-forward of the Level 3 fair value measurement is as follows: Balance at Issuance Net unrealized (gain)/loss Conversion Balance at March 31, 2018 267,000 $ (53,000) $ (58,000) $ 156,000 The carrying value of the Note is comprised of the following: March 31, 2018 Convertible Notes Principal $ 220,000 Fair value of embedded conversion option 156,000 Accrued Interest 15,204 Debt discount (133,590) Carrying value of Convertible Note $ 257,614 As of March 31, 2018, the estimated aggregate fair value of outstanding convertible notes payable is approximately $0.3 million. The fair value estimate is based on the estimated option value of the conversion terms. The estimated fair value represents a Level 3 measurement. Technical default The notes which are due in January 2018 are in technical default, although the obligation has not been called by the lender. The note agreement provided for such circumstances with the effect that the Company will record interest at the default interest rate of 28%.

Capital Stock Disclosure

Capital Stock Disclosure	12 Months Ended
	Mar. 31, 2018
Notes
Capital Stock Disclosure	NOTE 8 - CAPITAL STOCK Stock Subscriptions On April 12, 2015, we entered into a memorandum of understanding (“MOU”) with a group of investors, and subsequently on October 21, 2015, we entered into an Investment Agreement with these investors for $1,500,000 to be payable in several tranches. Upon payment of each tranche the Company was to issue shares to the investors equal to the value of the tranche divided by the higher of (i) $2.00 or (ii) the average of the closing sales price of the Company’s common stock on each of the five days prior to the date that payment for such tranche is due. The shares were to be issued to escrow until all payments had been made. Upon completion of the payments due under the agreements, the investors will have a twelve-month option to invest up to an additional $1,000,000 into the Company on the same terms. On June 7, 2016, we signed an Addendum (the “Addendum”) to the Investment Agreement providing for an additional $60,000 of investment on the same terms as the Investment Agreement. The funding was paid to the Company within the terms of the Addendum on June 8, 2016. Final Placement To date no shares have been issued to escrow due to management’s uncertainty over the investors’ appetite to complete the funding arrangement following a fall in share price. To date the investors are due to receive 530,000 shares for the $1,060,000 already invested. The final tranche of $500,000 was due in October 2016, but to date that payment has not been made. Conversion of convertible debt instruments During the year ended March 31, 2018, a holder of convertible debentures converted approximately $0.2 million in principal amount and accrued interest into approximately 4.2 million shares of common stock and a holder of convertible debt converted approximately $0.1 million in principal amount and accrued interest converted into approximately 6.0 million shares of common stock. Upon issuance of the stock the Company recognized a loss of approximately $0.1 million. Shares issued to satisfy accrued expenses In April 2017 the Company issued 0.2 million shares to a supplier in lieu of invoices worth approximately $24,000. In February 2018 the three directors of the Company converted approximately $0.2 million of unpaid fees and bonus into approximately 7.2 million shares of common stock. Upon issuance of the stock the Company recognized a loss of approximately $0.1 million. Stock compensation During the year ended March 31, 2018 the Company issued approximately 7.5 million shares to employees and directors for services. The Company recorded share based compensation of approximately $0.4 million in the statement of operations.

Commitments Disclosure

Commitments Disclosure	12 Months Ended
	Mar. 31, 2018
Notes
Commitments Disclosure	NOTE 9 - COMMITMENTS Leases on Property The Company has a $1,300 month to month lease on an office property in Sunnyvale, CA. In March 2018, the Company re-signed its annual lease on a Laboratory in Budapest, Hungary. The monthly lease payments total approximately $3,000, and the lease term was 1 year. The lessor may terminate upon non-payment of rent, and the Company may terminate if the laboratory is not operational for 15 days or more. Lease expense for the periods ended March 31, 2018 and 2017 was approximately $52,000 and $49,000.

Income Taxes Disclosure

Income Taxes Disclosure	12 Months Ended
	Mar. 31, 2018
Notes
Income Taxes Disclosure	NOTE 10 - INCOME TAXES The Company files income tax returns in the U.S. federal jurisdiction and the state of California. The income tax provision (benefit) consists of the following: For The Years Ended March 31, 2018 March 31, 2017 Federal: Current $ -- $ -- Deferred (115,000) (368,000) State and local: Current -- -- Deferred (142,000) (65,000) (257,000) (433,000) Change in valuation allowance 257,000 433,000 Income tax provision (benefit) $ -- $ -- The difference between the statutory federal tax rate and the effective tax rate is summarized below: For The Years Ended March 31, 2018 March 31, 2017 Federal tax at statutory rate: (31.0)% (34.0)% State taxes (net of Federal benefit) (6.0)% (5.8)% Permanent differences 4.4% 0.9% Other (0.0)% 0.0% Change in valuation allowance 12.8% 38.9% Change in federal tax rate 19.8% 0.0% Provision for Income Taxes 0.0% 0.0% The tax effects of temporary differences that give rise to the Company’s deferred tax assets and liabilities are as follows: As of March 31, 2018 2017 Deferred Tax Assets: Net operating loss carryforwards $ 1,005,000 $ 738,000 Accrued compensation 50,000 60,000 Gross deferred tax assets 1,055,000 798,000 Valuation allowance (1,055,000) (798,000) Deferred tax assets, net of valuation allowance -- -- Changes in valuation allowance $ (257,000) $ (433,000) As of March 31, 2018 and 2017, the Company provided a full valuation allowance against its net deferred assets since realization of these benefits is not more likely than not. As of March 31, 2018, the Company had federal and state net operating loss tax carryforwards of approximately $3.6 million. These net operating loss carryforwards expire in various amounts starting in 2029. The utilization of the federal and state net operating loss carryforwards will depend on the Company’s ability to generate sufficient taxable income prior to the expiration of the carryforwards. In addition, these net operating loss carryforwards are subject to annual limitations under Section 382 of the U.S. Internal Revenue Code when there is a greater than 50% ownership change, as determined under the regulations. Based on our analysis, there has been no such change of control during the years ended March 31, 2018 and 2017. As of March 31, 2018 and 2017, the Company had no unrecognized tax benefits. To date, no tax returns have been filed by the Company. Net operating losses cannot be used against future income until returns are filed. Until those tax returns are filed by the Company, all tax years will remain open to examination by federal tax and state tax jurisdictions. No income tax returns are currently under examination by taxing authorities. The Tax Cuts and Jobs Act (the “Act”) was enacted in December 2017 making significant changes to the Internal Revenue Code. Changes include but are not limited to (a) the reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017; (b) the transition of U.S. international taxation from a worldwide tax system to a territorial system; and (c) a one-time transition tax on the mandatory deemed repatriation of foreign earnings. The latter two changes are not expected to impact the Company. The change in tax law required the Company to remeasure existing net deferred tax assets using the lower rate expected to be in effect for the periods when the tax benefit is expected to be realized, resulting in an income tax expense of approximately $0.4 million which is fully offset by the corresponding tax benefit of $0.4 million from the corresponding reduction in the valuation allowance in the year ended March 31, 2018. There were no specific impacts of the Act that could not be reasonably estimated which the Company accounted for under the prior tax law. However, based on a continued analysis of the estimates and further guidance on the application of the law, it is possible that additional revisions may occur throughout the allowable one-year measurement period, as outlined in Staff Accounting Bulletin No. 118.

Subsequent Events, Disclosure

Subsequent Events, Disclosure	12 Months Ended
	Mar. 31, 2018
Notes
Subsequent Events, Disclosure	NOTE 11 - SUBSEQUENT EVENTS On April 30, 2018 a holder of convertible debentures converted approximately $0.1 million of principal and interest into approximately 1.6 million shares of common stock. On June 5, 2018, we entered into a securities purchase agreement (the "SPA") with an accredited investor (the “Buyer”) to issue Convertible Debentures (the “Debentures”) with a maturity date of one year after the issuance thereof in the aggregate principal amount of up to $0.3 million on similar terms to those referred to in Note 6 above.

Summary of Significant Accoun18

Summary of Significant Accounting Policies: Basis of Presentation Policy (Policies)	12 Months Ended
	Mar. 31, 2018
Policies
Basis of Presentation Policy	Basis of Presentation These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Summary of Significant Accoun19

Summary of Significant Accounting Policies: Principles of Consolidation (Policies)	12 Months Ended
	Mar. 31, 2018
Policies
Principles of Consolidation	Principles of Consolidation These financial statements include the accounts of the Company and its wholly-owned subsidiary.

Summary of Significant Accoun20

Summary of Significant Accounting Policies: Use of Estimates Policy (Policies)	12 Months Ended
	Mar. 31, 2018
Policies
Use of Estimates Policy	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.

Summary of Significant Accoun21

Summary of Significant Accounting Policies: Warrant Liability, Policy (Policies)	12 Months Ended
	Mar. 31, 2018
Policies
Warrant Liability, Policy	Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company's statements of operations. The fair value of the warrants issued by the Company has been estimated using a valuation pricing model, at each measurement date that incorporates various inputs including remaining contractual term, stock volatility, risk free rate and dividend yield.

Summary of Significant Accoun22

Summary of Significant Accounting Policies: Equity-linked Financial Instruments Policy (Policies)	12 Months Ended
	Mar. 31, 2018
Policies
Equity-linked Financial Instruments Policy	Equity-linked Financial Instruments Certain of the Company’s debt instruments include embedded derivatives that require bifurcation from the host contract under the provisions of ASC 815, Derivatives and Hedging. Under this guidance, the Company recognizes the embedded derivatives at fair value and records a gain or loss resulting from the change in fair values at the end of each reporting period. In connection with issuance of the Company’s Zhu convertible notes, beginning on July 3, 2017, the Company became contingently obligated to issue shares in excess of the 250 million authorized by shareholders. Consequently, the ability to settle these obligations with shares would be unavailable causing these and other share-settled obligations to potentially be settled in cash. The Company applies a sequencing policy regarding share settlement wherein equity-linked financial instruments with the earliest issuance date would be settled first. Thus, all equity-linked financial instruments, which are convertible or exercisable into common stock, issued concurrent or subsequent to the Zhu Notes are classified as derivative liabilities, with the exception of instruments related to employee share-based compensation.

Summary of Significant Accoun23

Summary of Significant Accounting Policies: Sequencing Policy (Policies)	12 Months Ended
	Mar. 31, 2018
Policies
Sequencing Policy	Sequencing As of July 3, 2017, the Company adopted a sequencing policy whereby all future equity-linked instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors.

Summary of Significant Accoun24

Summary of Significant Accounting Policies: Income Taxes Policy (Policies)	12 Months Ended
	Mar. 31, 2018
Policies
Income Taxes Policy	Income Taxes The Company recognizes income taxes on an accrual basis based on tax positions taken or expected to be taken in its tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense.

Summary of Significant Accoun25

Summary of Significant Accounting Policies: Fair Value of Financial Instruments Policy (Policies)	12 Months Ended
	Mar. 31, 2018
Policies
Fair Value of Financial Instruments Policy	Fair Value of Financial Instruments The Company's financial instruments consist of cash, accounts payable, convertible debentures and a loan payable to a related party. The carrying amounts of these financial instruments approximate fair value due either to length of maturity or interest rates that approximate prevailing rates unless otherwise disclosed in these financial statements.

Summary of Significant Accoun26

Summary of Significant Accounting Policies: Share Subscriptions Policy (Policies)	12 Months Ended
	Mar. 31, 2018
Policies
Share Subscriptions Policy	Share Subscriptions Under the terms of a subscription agreement, the Company has received funds in advance of the issuance of stock. The stock is issuable to the investors once the full subscription proceeds are received, which, as of the date of this filing, has not yet occurred. The Company recorded the advance in equity.

Summary of Significant Accoun27

Summary of Significant Accounting Policies: Earnings (loss) Per Share Policy (Policies)	12 Months Ended
	Mar. 31, 2018
Policies
Earnings (loss) Per Share Policy	Earnings (Loss) per Share The Company calculates earnings per share using basic net income (loss) per common share be computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. The Company does not compute diluted earnings per share because to do so would be anti-dilutive. March 31, March 31, 2018 2017 Potentially dilutive securities Secured convertible debentures (Note 6) 12,406,000 3,420,000 Convertible debt related party (Note 7) 3,914,000 -- Stock subscription 530,000 530,000

Summary of Significant Accoun28

Summary of Significant Accounting Policies: Recent Accounting Standards (Policies)	12 Months Ended
	Mar. 31, 2018
Policies
Recent Accounting Standards	Recently Issued Accounting Standards Fiscal 2018 Accounting Pronouncement Adoptions In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Certain qualitative and quantitative disclosures are required, as well as a retrospective recognition and measurement of impacted leases. The new ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements. In June 2018, the FASB issued Accounting Standards Update (ASU) 2018-07 intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. This ASU expands the scope of Topic 718, Compensation-Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity-Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other companies, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company's adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements.

Summary of Significant Accoun29

Summary of Significant Accounting Policies: Earnings (loss) Per Share Policy: Schedule of Potentially Dilutive Securities (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Schedule of Potentially Dilutive Securities	March 31, March 31, 2018 2017 Potentially dilutive securities Secured convertible debentures (Note 6) 12,406,000 3,420,000 Convertible debt related party (Note 7) 3,914,000 -- Stock subscription 530,000 530,000

Related Party Transactions Di30

Related Party Transactions Disclosure: Schedule of Related Party Transaction Costs (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Schedule of Related Party Transaction Costs	Years to March 31 2018 2017 Operating expenses: Toth and Associates LTD $ 320,000 $ 144,000 Capro LTD 207,000 120,000 Eden Professional LTD 147,000 75,000 Max Zhu Consulting 18,000 24,000 Total related party transactions $ 692,000 $ 363,000

Secured Convertible Debenture31

Secured Convertible Debentures Disclosure: Convertible Debt, Embedded Derivative - key inputs (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Convertible Debt, Embedded Derivative - key inputs	March 31, 2018 March 31, 2017 Stock price $0.06 $0.16-$0.23 Probability of Triggering Date 100% 23%-35% Volatility 300% 207% Risk-free rate 1% 1% Discount rate 0% 40%

Secured Convertible Debenture32

Secured Convertible Debentures Disclosure: Convertible Debt, Beneficial Conversion Feature - key inputs (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Convertible Debt, Beneficial Conversion Feature - key inputs	March 31, 2018 March 31, 2017 Stock price $0.06 $0.16-$0.23 Exercise price $0.06 $0.15-$0.21 Volatility 300% 207% Contractual term 1 year 1 year Risk-free rate 1% 1% Discount rate 0% 40%

Secured Convertible Debenture33

Secured Convertible Debentures Disclosure: Fair Value Measured on Embedded Derivative (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Fair Value Measured on Embedded Derivative	Balance at March 31, 2017 Issuance Net unrealized (gain)/loss Balance at March 31, 2018 24,000 $ 685,000 $ 27,000 $ 736,000

Secured Convertible Debenture34

Secured Convertible Debentures Disclosure: Schedule of Carrying Values of Convertible Debt Instruments (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Schedule of Carrying Values of Convertible Debt Instruments	March 31, 2018 March 31, 2017 Secured Convertible Debentures Principal $ 750,000 $ 450,000 Fair value of embedded derivative 736,000 24,000 Accrued interest 22,264 -- Debt discount (561,104) (151,744) Carrying value of Secured Convertible Debentures $ 947,160 $ 322,256

Convertible Debt Related Part35

Convertible Debt Related Parties Disclosure: Embedded Derivative - key inputs (related party) (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Embedded Derivative - key inputs (related party)	Key Inputs Stock price $0.02- $0.07 Contractual term 0.1 - 1.0 years Volatility 275%-300% Risk-free rate 1%

Convertible Debt Related Part36

Convertible Debt Related Parties Disclosure: Fair Value Measured on Embedded Derivative (related party) (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Fair Value Measured on Embedded Derivative (related party)	Balance at Issuance Net unrealized (gain)/loss Conversion Balance at March 31, 2018 267,000 $ (53,000) $ (58,000) $ 156,000

Convertible Debt Related Part37

Convertible Debt Related Parties Disclosure: Schedule of Carrying Values of Convertible Debt Instruments (related party) (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Schedule of Carrying Values of Convertible Debt Instruments (related party)	March 31, 2018 Convertible Notes Principal $ 220,000 Fair value of embedded conversion option 156,000 Accrued Interest 15,204 Debt discount (133,590) Carrying value of Convertible Note $ 257,614

Income Taxes Disclosure_ Schedu

Income Taxes Disclosure: Schedule of Income Tax Provision (Benefit) (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Schedule of Income Tax Provision (Benefit)	For The Years Ended March 31, 2018 March 31, 2017 Federal: Current $ -- $ -- Deferred (115,000) (368,000) State and local: Current -- -- Deferred (142,000) (65,000) (257,000) (433,000) Change in valuation allowance 257,000 433,000 Income tax provision (benefit) $ -- $ --

Income Taxes Disclosure_ Sche39

Income Taxes Disclosure: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation	For The Years Ended March 31, 2018 March 31, 2017 Federal tax at statutory rate: (31.0)% (34.0)% State taxes (net of Federal benefit) (6.0)% (5.8)% Permanent differences 4.4% 0.9% Other (0.0)% 0.0% Change in valuation allowance 12.8% 38.9% Change in federal tax rate 19.8% 0.0% Provision for Income Taxes 0.0% 0.0%

Income Taxes Disclosure_ Sche40

Income Taxes Disclosure: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Mar. 31, 2018
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	As of March 31, 2018 2017 Deferred Tax Assets: Net operating loss carryforwards $ 1,005,000 $ 738,000 Accrued compensation 50,000 60,000 Gross deferred tax assets 1,055,000 798,000 Valuation allowance (1,055,000) (798,000) Deferred tax assets, net of valuation allowance -- -- Changes in valuation allowance $ (257,000) $ (433,000)

Going Concern Disclosure (Detai

Going Concern Disclosure (Details)	Mar. 31, 2018USD ($)
Details
working capital deficit	$ 1,873,204

Summary of Significant Accoun42

Summary of Significant Accounting Policies: Earnings (loss) Per Share Policy: Schedule of Potentially Dilutive Securities (Details) - shares	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Secured convertible debentures (anti-dilutive shares)
Potentially dilutive securities	12,406,000	3,420,000
Convertible debt related party (anti-dilutive shares)
Potentially dilutive securities	3,914,000
Stock subscription (anti-dilutive shares)
Potentially dilutive securities	530,000	530,000

Material Agreements Disclosure

Material Agreements Disclosure (Details) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2018
Agreement with NovAliX Deutschland GmbH
Amount payable for license		$ 80,000
Accrued interest		35,000
Purdue Research Foundation Licensing Agreement - DJ-1 Small Molecule
Amount payable for license		$ 150,000
Cambridge Enterprise Licensing Agreement - Tau
Payments made per agreements	$ 13,000

Related Party Transactions Di44

Related Party Transactions Disclosure: Schedule of Related Party Transaction Costs (Details) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Related party consulting fees incurred	$ 692,000	$ 363,000
Toth and Associates LTD
Related party consulting fees incurred	320,000	144,000
Capro LTD
Related party consulting fees incurred	207,000	120,000
Eden Professional LTD
Related party consulting fees incurred	147,000	75,000
Max Zhu
Related party consulting fees incurred	$ 18,000	$ 24,000

Related Party Transactions Di45

Related Party Transactions Disclosure (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Accounts payable and accrued expenses - related party	$ 200,000	$ 300,000
Toth and Associates LTD
Monthly compensation	12,000
Fixed bonus, to be paid if certain conditions are met	50,000
Capro LTD
Monthly compensation	10,000
Fixed bonus, to be paid if certain conditions are met	50,000
Eden Professional LTD
Monthly compensation	6,000
Fixed bonus, to be paid if certain conditions are met	$ 50,000

Secured Convertible Debenture46

Secured Convertible Debentures Disclosure (Details) - USD ($) shares in Millions	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounts payable and accrued expenses	$ 606,751	$ 377,893
Gain (loss) on extinguishment of debt	241,025
Debt discount recorded	600,000
Conversion of convertible debt instruments(1)
Amount of debt being converted	$ 200,000
Shares of common stock issued for debt conversion	4.2
Triggering Date Premium
Accounts payable and accrued expenses	$ 50,000,000,000
Securities purchase agreement with an accredited investor
Estimated aggregate fair value of all outstanding convertible notes payable	$ 900,000

Secured Convertible Debenture47

Secured Convertible Debentures Disclosure: Fair Value Measured on Embedded Derivative (Details)	12 Months Ended
	Mar. 31, 2018USD ($)
Securities purchase agreement with an accredited investor
Net unrealized gain (loss) on embedded derivative	$ 27,000

Secured Convertible Debenture48

Secured Convertible Debentures Disclosure: Schedule of Carrying Values of Convertible Debt Instruments (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Convertible debentures	$ 947,160	$ 322,256
Secured Convertible Debentures - Principal
Convertible debentures	750,000	450,000
Secured Convertible Debentures - Fair vale of embedded derivative
Convertible debentures	736,000	24,000
Secured Convertible Debentures - Accrued interest
Convertible debentures	22,264
Secured Convertible Debentures - Debt discount
Convertible debentures	$ (561,104)	$ (151,744)

Convertible Debt Related Part49

Convertible Debt Related Parties Disclosure (Details) shares in Millions	12 Months Ended
	Mar. 31, 2018USD ($)shares
Convertible debentures related party	$ 257,614
Convertible debt arrangement with Max Zhu 18-20%
Convertible debentures issued	$ 220,000
Shares of common stock issued for debt conversion | shares	6
Convertible debentures related party	$ 100,000
Convertible debt arrangement with Max Zhu 5%
Convertible debentures issued	120,000
Convertible debt arrangements with Max Zhu
Estimated aggregate fair value of all outstanding convertible notes payable	$ 300,000

Convertible Debt Related Part50

Convertible Debt Related Parties Disclosure: Fair Value Measured on Embedded Derivative (related party) (Details)	12 Months Ended
	Mar. 31, 2018USD ($)
Convertible debt arrangements with Max Zhu
Net unrealized gain (loss) on embedded derivative	$ 53,000

Convertible Debt Related Part51

Convertible Debt Related Parties Disclosure: Schedule of Carrying Values of Convertible Debt Instruments (related party) (Details)	Mar. 31, 2018USD ($)
Convertible debentures related party	$ 257,614
Secured Convertible Debentures - Principal
Convertible debentures related party	220,000
Secured Convertible Debentures - Fair vale of embedded derivative
Convertible debentures related party	156,000
Secured Convertible Debentures - Accrued interest
Convertible debentures related party	15,204
Secured Convertible Debentures - Debt discount
Convertible debentures related party	$ (133,590)

Capital Stock Disclosure (Detai

Capital Stock Disclosure (Details) shares in Millions	12 Months Ended
	Mar. 31, 2018USD ($)shares
Amount of accrued expenses satisfied | $	$ 350,560
Convertible debt arrangement with Max Zhu 18-20%
Amount of debt being converted | $	$ 100,000
Shares of common stock issued for debt conversion | shares	6
Conversion of convertible debt instruments(1)
Amount of debt being converted | $	$ 200,000
Shares of common stock issued for debt conversion | shares	4.2
To a supplier in lieu of invoices
Common stock issued for accrued expenses | shares	0.2
Amount of accrued expenses satisfied | $	$ 24,000
For unpaid director fees and bonus
Common stock issued for accrued expenses | shares	7.2
Amount of accrued expenses satisfied | $	$ 200,000
Employees and directors for services
Common stock issued as share-based compensation | shares	7.5

Commitments Disclosure (Details

Commitments Disclosure (Details) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Lease expense	$ 52,000	$ 49,000
Office property in Sunnyvale, CA
Monthly payments required on Property Leases	1,300
Laboratory in Budapest, Hungary
Monthly payments required on Property Leases	$ 3,000

Income Taxes Disclosure_ Sche54

Income Taxes Disclosure: Schedule of Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Details
Deferred federal income tax expense (benefit)	$ (115,000)	$ (368,000)
Deferred state and local tax expense (benefit)	(142,000)	(65,000)
Change in valuation allowance of deferred tax expense	$ 257,000	$ 433,000

Income Taxes Disclosure_ Sche55

Income Taxes Disclosure: Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Details
Federal tax at statutory rate	(31.00%)	(34.00%)
State taxes (net of Federal benefit)	(6.00%)	(5.80%)
Permanent difference	4.40%	0.90%
Change in Valuation Allowance (%)	12.80%	38.90%
Change in federal tax rate	19.80%	0.00%

Income Taxes Disclosure_ Sche56

Income Taxes Disclosure: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Details
Net operating loss carried forward	$ 1,005,000	$ 738,000
Accrued Compensation	50,000	60,000
Gross deferred tax assets	1,055,000	798,000
Valuation Allowance	(1,055,000)	(798,000)
Change in valuation allowance for deferred tax assets	$ (257,000)	$ (433,000)

Income Taxes Disclosure (Detail

Income Taxes Disclosure (Details) $ in Millions	Mar. 31, 2018USD ($)
Details
Net tax loss carried forward	$ 3.6

Subsequent Events, Disclosure (

Subsequent Events, Disclosure (Details) - Convertible debentures converted - April 30, 2018 shares in Millions, $ in Millions	3 Months Ended
	Jul. 13, 2018USD ($)shares
Amount of debt being converted | $	$ 0.1
Shares of common stock issued for debt conversion | shares	1.6